PSSD Collaborative Research

A forum dedicated to collaborative research into PSSD (Post-SSRI Sexual Dysfunction).

Skip to content

  • Home ‹ FORUMS ‹ PSSD related research
  • Change font size
  • Print view
  • Download as PDF
  • FAQ
  • Members
  • Register
  • Login
  • Advanced search

5α-Reductase / PFS connections Research

This is a place to post research you have done on the topic along with your conclusions.

Moderators: Ghost, Sonny

Post a reply
First unread post • 22 posts • Page 3 of 3 • 1, 2, 3

Re: 5α-Reductase / PFS connections Research

Unread postby Bigmum » Thu May 11, 2017 11:26 pm

But if someone wonts you can try contact with him....he likes spread awernes cause IT makes him popular
Sorry for my bad (terrible) English.
Bigmum
Newly Registered User
 
Posts: 689
Joined: Thu Nov 03, 2016 9:53 am
  • Private message
Top

Share On:

Share on Facebook Facebook Share on Twitter Twitter Share on Reddit Reddit Share on Tumblr TumblrShare on Google+ Google+

Re: 5α-Reductase / PFS connections Research

Unread postby Recovery » Sun May 14, 2017 2:29 pm

SOMERSET, N.J., April 18, 2017 – Post-finasteride syndrome (PFS) patients suffer from altered levels of critical brain-function regulators, including neuroactive steroids, according to a new clinical study published in The Journal of Steroid Biochemistry and Molecular Biology.

Titled Neuroactive Steroid Levels and Psychiatric and Andrological Features in Post-Finasteride Patients, the three-year study also uncovered evidence of neuropathy of the pudendal nerve among those with severe erectile dysfunction.

In all, 16 men with PFS and 25 control patients were evaluated in the study conducted at the University of Milano’s Department of Pharmacological and Biomolecular Sciences by a team of 12 researchers led by Roberto Cosimo Melcangi, Ph.D. The PFS patients had discontinued finasteride for a median of 5.4 years at the time of evaluation, and had no prior history of erectile dysfunction or depression prior to finasteride use.

Key findings of the study include broad effects on plasma and cerebrospinal fluid (CSF) neuroactive steroid levels observed in 14 PFS patients, as compared to 25 controls. Statistically significant decreased levels of DHT, pregnenolone, progesterone, 17-beta estradiol and dihydroprogesterone (DHP), and increased levels of DHEA, testosterone and 3-alpha diol were observed in the CSF of PFS patients.


In plasma, statistically significant decreased levels of DHP and allopregnanolone, and increased levels of pregnenolone, DHEA and testosterone were observed.

Decreased plasma levels of allopregnanolone and decreased CSF levels of progesterone are common features of anxious/depressive symptomatology. Important physiologic effects of neuroactive steroids on brain function include neuroendocrine control of reproduction and sex behavior, synaptic plasticity, morphology of neurons and astrocytes, maintenance of cytoskeleton proteins and myelin, adult neurogenesis, and cognition-related functions.

The study also identified, in 25 percent of PFS patients, the first objective evidence of abnormal somatosensory evoked potentials (SSEP) of the pudendal nerve. Abnormal SSEP findings were observed in PFS patients with severe ED.

Peripheral neuropathy of the pudendal nerve, the major nerve supplying the genitals that is critical for peripheral neurogenic control of erection, in PFS patients is a novel finding that demonstrates for the first time involvement of the peripheral nervous system in PFS patients with severe ED.

Additionally, 50 percent of the PFS patients were diagnosed with major depression based on the results from validated questionnaires, the Mini-International Neuropsychiatric Interview, the Beck Depression Inventory and the Beck Anxiety Inventory.

Such depression represents the first confirmation of findings in research led by Shalendar Bhasin, MD and published last year in The Journal of Clinical Endocrinology & Metabolism (Characteristics of Men Who Report Persistent Sexual Symptoms after Finasteride Use for Hair Loss), which suggested that men who experience persistent sexual dysfunction after discontinuing finasteride have “neurobiological abnormalities.”

“Among the most important milestones of Professor Melcangi’s research is that it builds directly on Dr. Bhasin’s work,” said Dr. John Santmann, CEO of the Post-Finasteride Syndrome Foundation, which sponsored the study.
Recovery
Newly Registered User
 
Posts: 101
Joined: Fri Aug 26, 2016 2:35 am
  • Private message
Top

Previous

Post a reply
22 posts • Page 3 of 3 • 1, 2, 3

Return to PSSD related research

Who is online

Users browsing this forum: No registered users and 1 guest

  • Home
  • The team • Delete all board cookies • All times are UTC - 8 hours
Powered by phpBB® Forum Software © phpBB Group
Contact